Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)

01:00 EDT 11 Oct 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
CIU is a skin condition characterized by red, swollen, itchy hives Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticar...

Other Sources for this Article

Genentech
Media Contact:
Chris Vancheri, 650-467-6800
or
Investor Contacts:
Thomas Kudsk Larsen, 650-467-2016
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)"

Search BioPortfolio:

Relevant Topics

Dermatology · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers a range of diseases including skin allergies, alopecia, Behcet'...

Allergies · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Advertisement
Advertisement

Searches Linking to this Story